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Pure ovarian choriocarcinoma is an extremely rare malignancy that can be gestational or non-gesta-
tional in origin.  Silver-Russell syndrome (SRS) is a rare congenital developmental disorder character-
ized by pre- and postnatal growth failure,  relative macrocephaly,  a triangular face,  hemihypotrophy,  
and ﬁfth-ﬁnger clinodactyly.  We report a rare case of pure ovarian choriocarcinoma occurring in a 
19-year-old woman with SRS.  Following surgery,  multiple chemotherapy courses were eﬀective and 
she was free of disease at the 10-month follow-up.
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ure ovarian choriocarcinoma is an extremely 
rare malignancy that can be gestational or non-
gestational in origin.  The gestational type may arise 
from the gestational tissue of an ectopic ovarian preg-
nancy or present as a metastasis from a uterine or 
tubal choriocarcinoma.  The non-gestational type is a 
rare germ-cell tumor with trophoblastic diﬀerentia-
tion [1].  The estimated incidence of gestational ovar-
ian choriocarcinoma is 1 in 369 million pregnancies 
[2].  Non-gestational ovarian choriocarcinoma corre-
sponds to less than 0.6ｵ of all ovarian neoplasms;  
the pure type is extremely uncommon [3].
　 Silver-Russell syndrome (SRS) is a rare congenital 
developmental disorder characterized by pre- and 
postnatal growth failure,  relative macrocephaly,  a 
triangular face,  hemihypotrophy,  and ﬁfth-ﬁnger 
clinodactyly.  Most people aﬀected by SRS show nor-
mal intelligence [4].  Although some SRS cases are 
complicated by various kinds of gonadal dysgenesis,  a 
case of normal pregnancy and delivery has been 
reported [5].  SRS occurs sporadically; often,  no 
genetic cause can be clearly identiﬁed.  In recent years,  
more than 38ｵ of patients have been shown to have 
hypomethylation in the imprinting control region 1 of 
11p15 and around 10ｵ of patients carry a maternal 
uniparental disomy of chromosome 7 [6-7].  Interestingly,  
maternally imprinted PEG10 and SGCE,  separated by 
～2.15 Mb from the syncytin (HERV-W) gene at 7q21.3,  
are implicated in both SRS and choriocarcinoma [8],  
and may be associated with each other.  We herein 
report a unique case of a purely ovarian choriocarci-
noma occurring in a 19-year-old woman with SRS.
Case Report
　 A 19-year-old woman with SRS was referred to us 
after suﬀering lower abdominal pain for several days 
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and menstrual delay for 2 months although her previ-
ous menstrual cycles had been regular.  She had 
engaged in sexual intercourse,  so pregnancy was a 
possibility.  Her height was 126.4cm but her body 
weight was only 24.5kg because of growth failure from 
SRS.  Physical examination revealed abdominal ten-
derness and anemia (Hb8.2g/dL).  Ultrasound showed 
a 10-cm solid mass at the pelvis and ﬂuid in the 
Douglas pouch.  Her serum level of β-human chorionic 
gonadotropin (β-hCG) was 373,170mIU/mL.  
Emergency surgery was performed for abdominal 
bleeding due to suspected ectopic pregnancy.  Intra-
operatively,  a dark-red,  soft,  friable 10-cm mass was 
found in place of the left ovary and was bleeding;  
hence,  a left salpingo-oophorectomy was performed 
(Fig.  1A).  The right ovary and uterus were normal in 
appearance.  Microscopically,  the tumor was con-
ﬁrmed to be a pure choriocarcinoma (Fig.  1B,  C).  
Two weeks post-surgery,  her serum β-hCG level was 
58,855mIU/mL.  Computed tomography (CT) revealed 
2 lung metastases (the larger of which was 5mm) and 
multiple disseminated peritoneal metastases (Fig.  2A,  
B).  Magnetic resonance imaging (MRI) showed a 
58-mm mass in her left pelvis (Fig.  2C,  D).  The 
patient scored 8 on the International Federation of 
Gynecology and Obstetrics (FIGO) scoring system,  
placing her in the high-risk gestational trophoblastic 
neoplasia group (ｧ7),  at FIGO stage III.  Therefore,  
the patient was treated with EMA/CO chemotherapy,  
including etoposide (100mg/m2 on days 1-2),  metho-
trexate (300mg/m2 on day 1),  actinomycin-D (0.5mg/
kg on day 1-2),  cyclophosphamide (600mg/m2 on day 
8),  and vincristine (1,000mg/m2 on day 8) at 14-day 
intervals.  After one cycle of chemotherapy,  she suf-
fered from strong side eﬀects―Grade 4 neutropenia 
and Grade 3 hepatic dysfunction―so we reduced the 
chemotherapy doses to 70ｵ and extended the interval.  
She tolerated a total of 6 cycles of chemotherapy with 
Grade 1-2 neutropenia,  nausea and hepatic dysfunc-
tion.  Her serum β-hCG level decreased to within the 
normal range after 5 cycles of chemotherapy,  and then 
through the 6th cycle of EMA/CO chemotherapy 
(Fig.  3).  After 6 cycles of chemotherapy,  CT and 
MRI showed that most of the lung metastases and 
peritoneal disseminations had disappeared,  but small 
lesions in her left pelvis remained.  Positron emission 
tomography (PET)-CT showed ﬂuorodeoxyglucose 
uptake by that lesion (SUVmax＝3.20) (Fig.  4).  Four 
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Fig. 1　 The left ovary had been replaced by a dark-red,  soft,  
friable 10-cm mass (A).  Microscopically,  the proliferation of 
cytotrophoblast and syncytiotrophoblast with widespread necrosis 
was detected.  The tumor was conﬁrmed to be a pure choriocarci-
noma (Hematoxylin and eosin stain) (B,  C).
weeks after the ﬁnal chemotherapy,  we observed her 
abdominal cavity under laparoscopy and found a small,  
dark brown tumor at the stump of left ligament of the 
ovary (Fig.  5).  We resected it as much as possible;  
specimens showed no viable residual tumor.  The 
patient remains without evidence of disease after 10 
months of follow-up.
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Fig. 2　 Computed tomography (CT) showed lung metastasis of 5mm (A) and peritoneal dissemination (B).  CT and magnetic resonance 
imaging (MRI) showed a mass of 58mm in her left pelvis (C and D).
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Fig. 3　 The serum β-hCG level steadily decreased after chemotherapy started.  It was within the normal range after 5 cycles of chemo-
therapy.
Discussion
　 SRS was ﬁrst described by Silver and co-workers 
in 1953,  and then independently by Russell in 1954 
[9,  10].  It is a rare,  genetically heterogeneous dis-
order occurring in approximately 1 in 50,000-100,000 
births,  in which patients demonstrate intrauterine and 
postnatal growth retardation,  relative macrocephaly,  
triangular faces,  asymmetry and feeding diﬃculties 
[4].  In general the features of the syndrome are most 
pronounced in young children and become less obvious 
as the patient becomes older [11].  The condition 
occurs sporadically and,  in many cases,  no genetic 
cause can be clearly identiﬁed.  Recent studies have 
shown that epimutation (hypomethylation) of the pater-
nally derived diﬀerentially methylated region (DMR) 
upstream of H19 (H19-DMR) on chromosome 11p15.5,  
and maternal uniparental disomy for chromosome 7 
(upd(7)mat) account for ～45ｵ and 5-10ｵ of SRS 
patients,  respectively [4-8].  Interestingly,  maternally 
imprinted PEG10 and SGCE,  separated by ～2.15 Mb 
from the syncytin (HERV-W) gene at 7q21.3,  are 
implicated in both SRS and choriocarcinoma [8,  
12-16].  PEG10,  which is normally a paternally 
expressed gene,  is predominantly expressed in the 
placenta and testis and to a lesser extent in the brain 
and lung [17],  and codes for a protein homologous to 
mouse MyEF-3 (myelin expression factor 3),  which is 
presumed to be necessary for producing myelin-bind-
ing protein (MBP) and has been shown to participate 
in myelinating neurons [18].  SGCE,  the epsilon 
member of the sarcoglycan family,  is a component of 
the transmembrane dystrophin-glycoprotein (DGC) 
complex.  It mediates communication between the 
muscle cytoskeleton and extracellular matrix by stabi-
lizing membranes [19].  As these neighboring genes 
are maternally imprinted in SRS and choriocarcinoma,  
there is some possibility that they link to placental and 
fetal development.  This is the ﬁrst case of pure ovar-
ian choriocarcinoma described in a patient with SRS.  
In this case,  maternally imprinted PEG10 and SGCE 
may have played a role in the histogenesis.
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Fig. 4　 After 6 courses of chemotherapy,  the tumor of the left pelvis had become smaller but still remained (A); positron emission 
tomography (PET)-CT revealed the uptake of ﬂuorodeoxyglucose (SUVmax＝3.20) (B).
Fig. 5　 A small,  dark brown tumor at the stump of the left ligament of the ovary was observed during laparoscopy.
　 Pure ovarian choriocarcinoma is an extremely rare 
malignancy which can be gestational or non-gestational 
in origin.  Diﬀerentiating between a gestational and 
non-gestational origin is important because non-gesta-
tional choriocarcinoma of the ovary is generally believed 
to have a poor prognosis.  However,  in the reproduc-
tive-aged group,  distinguishing between the two is 
often unclear,  because of both their rarity and the lack 
of distinctive ultrastructural or immunohistochemical 
diﬀerences [3,  20,  21].  Molecular genetic analysis 
can reliably identify the genetic origin of pure ovarian 
choriocarcinomas [22-25],  but is an expensive tech-
nique with limited availability,  so we could not utilize 
it in this case.  We strongly suspected a gestational 
rather than non-gestational origin because the patient 
had intercourse 2 months before the surgery and noted 
interrupted menses; hence,  there was the possibility 
of an ectopic ovarian pregnancy.  Furthermore,  the 
tumorʼs microscopic appearance showed a pure chorio-
carcinoma without another germ cell tumor component.
　 As the deﬁnitive treatment modality for pure ovar-
ian choriocarcinoma has not been established owing to 
its low incidence,  it is generally treated by the same 
protocols used for ovarian germ-cell tumor and gesta-
tional trophoblastic disease; in recent years,  many 
cases have been treated by cytoreductive surgery fol-
lowed by post-operative chemotherapy [1,  21].  Our 
patient was treated with EMA/CO therapy after 
tumor resection,  as her multiple metastases and large 
lesion remnants required more aggressive combination 
chemotherapy.  The patient responded well to the 
chemotherapy with a satisfactory decrease in serum 
β-hCG level.  EMA/CO therapy is very eﬀective for 
choriocarcinoma [26].  Another patient of ours who 
presented with choriocarcinoma after a term delivery 
has survived for more than 25 years in complete 
remission; she initially had lung and brain metastases 
with motor aphasia and hemiplegia,  and was treated 
by an EMA/CO regimen [27].
　 Although the present patientʼs serum β-hCG level 
was normalized,  pelvic lesion remnants were detected 
by MRI.  Observation and laparoscopy-guided biopsy 
were very useful in deciding to end the treatment.  We 
saw no evidence of recurrence or metastasis at the 
10-month follow-up.  Close observation of serum β-hCG 
levels and imaging examinations is necessary because 
pure ovarian choriocarcinoma is aggressive with a high 
risk of metastasis.
　 In conclusion,  we report the ﬁrst known case of a 
purely ovarian choriocarcinoma occurring in a patient 
with SRS.  Maternally imprinted PEG10 and SGCE 
have been reported to be implicated in both SRS and 
choriocarcinoma.  This case may have occurred because 
of this common genetic cause.
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